Clinical Trials Logo
  1. Home
  2. SARS-CoV2 Infection
  3. NCT04787510
  4. Details
NCT04787510 Clinical Trial

COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection

SARS-COV2 Infection Clinical Trial

Official title:
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04787510
Other study ID # 895/23-12-2020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 23, 2020
Est. completion date June 23, 2021

Study information
Verified date September 2021
Source University Hospital, Ioannina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Effect of Covid-19 disease in clotting factors levels in hospitalized patients

Description:

Effect of Covid-19 disease in clotting factors levels in hospitalized patients positive for sars-cov2 infection. Association between clotting factors levels and disease severity,morbidity and mortality in these patients. Effect of anticoagulant therapy in the clotting factors' levels in these patients

Recruitment information / eligibility
Status Completed
Enrollment 50
Est. completion date June 23, 2021
Est. primary completion date May 23, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - AGE> 18 - SINGED INFORMED CONSENT FORM - POSITIVE PCR TEST FOR SARS-COV2 INFECTION - FINDINGS IN CXR OR CT OF THE LUNGS CONSISTENT WITH INFECTION OF LOWER RESPIRATORY TRACT Exclusion Criteria: - AGE<18 - DENIAL TO PROVIDE INFORMED CONSENT FORM - HISTORY OF MALIGNANCY - PRIOR USE OF ANTICOAGULANT THERAPY - PRIOR USE OF STEROIDS LONGER THAN 14 DAYS - LACTATION-PREGNANCY

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• low molecular weight Heparin as standard of care treatment
STANDARD OF CARE

Locations
Country Name City State
Greece University General Hospital of Ioannina Ioánnina Epirus

Sponsors (2)
Lead Sponsor Collaborator
University Hospital, Ioannina INTERNAL MEDICINE DEPARTMENT, 1ST WARD

Country where clinical trial is conducted

Greece, 

Outcome
Type Measure Description Time frame Safety issue
Primary EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS leves of cloting factors before and after treatment with LMWH 6 MONTHS
See also
  Status Clinical Trial Phase
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Recruiting NCT05311410 - Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures N/A
Active, not recruiting NCT05073718 - SARS-CoV-2 and Acetylsalicylic Acid (SARA) Phase 3
Completed NCT05055505 - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions N/A
Completed NCT05055492 - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions N/A
Completed NCT05060510 - The School SPIT Study - COVID-19 Testing in Secondary Schools N/A
Completed NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Completed NCT05449392 - Topical Antibacterial Agents for Prevention of COVID-19 Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT05172024 - Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT05030974 - RECOVAC Repeated Vaccination Study Phase 4
Withdrawn NCT05067946 - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines Phase 2/Phase 3
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Completed NCT04551911 - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Phase 2
Completed NCT04953039 - Use of Saliva for COVID-19 Diagnosis